You might be onto something if the app was being pitched at a hospital or GP setting in suburban Australia.
However a hospital, an X-ray & a full clinical diagnosis for common resp. conditions (which requires access to the full range of diagnostic tools) by a doctor is not currently available globally to/or deemed necessary by many countries for all patients. That's where remote clinics, nurse practitioners & Telehealth fits in.
RAP is initially taking ResApp (if fully validated & approved) to the European tele-health market which is much more evolved than it is Australia & on a steep growth curve. Beyond that (IMHO) there are broad applications for app inc. ED's, screening (pre-employment, airports) remote medicine and primary health care settings (home & community) just to name a few.
- Forums
- ASX - By Stock
- Ann: Positive Results for Australian Prospective Paediatric Study
You might be onto something if the app was being pitched at a...
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RAP (ASX) Chart |
Day chart unavailable
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online